Brooklyn Bridge, New York City, USA


Funding Partners


AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.

AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario.

For more information, please visit their website:


Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc. invests more than
US $7 billion annually in R&D to discover and develop innovative life-saving and life-enhancing medicines in a wide range of therapeutic areas.

Their diversified healthcare portfolio includes human and animal biologic and small-molecule medicines and vaccines, and many of the world’s best-known consumer products.

For more information, please visit their website:


GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For more information, please visit their website:


Networks of Centres of Excellence (NCE)

In August 2014, the NCE selected the NEOMED Institute as a Centre of Excellence for Commercialization and Research (CECR).

Since its creation in 1989, the NCE program has successfully brought together the best minds in many disciplines and sectors to solve critical social, economic, and health issues for Canadians.

For more information, please visit their website:


The Ministère de l’Économie, de la Science et de l’Innovation (MESI) implements measures and programs to foster and support growth in the economy, investments, and employment.

Through its team of experts located in Québec’s 17 administrative regions, the MESI proposes an integrated approach that includes:

In addition, the Ministère elaborates policies in the economic, fiscal, budgetary, and financial fields.

For more information, please visit their website:



On December 7th, 2018, the City of Montreal granted financial support to the NEOMED Institute for the implementation of the first CIC in life sciences and health technologies (LSHT).

As part of its new 2018-2022 Economic Development Strategy Accélérer Montréal, the City of Montreal plans to set up CICs on its territory in order to improve the ecosystem of business sectors related to the orientations of its strategy.

CIC’s primary mission will be to facilitate the development and integration of innovative technologies, processes and approaches at all levels of the organization and at all stages of the corporate lifecycle, most notably at the growth stage. One of the objectives is to increase the productivity of companies so that they become more efficient and more competitive in the global market.

Among the targeted sectors of activity, in addition to LSHT, there is:


For more information, please visit:


Janssen Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including:

For more information, please visit their website:

Strategic Partners


The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), based at the Université de Montréal (UdeM), is a non-profit organization whose mandate is to accelerate the discovery, development, and commercialization of novel drugs and therapies originating from the Institute for Research in Immunology and Cancer (IRIC), other UdeM scientific research units, and collaborating centres.

IRICoR invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially promising projects. Projects supported by IRICoR have access to IRIC’s drug discovery infrastructure and professionals with expertise from the pharmaceutical industry.

For more information, please visit their website:


Through unique research and training programs, Mitacs is developing the next generation of innovators with vital scientific and business skills.

In partnership with companies, government and academia, Mitacs is supporting a new economy using Canada’s most valuable resource – its people.

For more information, please visit their website:


Created in 1998, Genopole has a threefold mission:

For more information, please visit:

Research Partners

logo Q-CROC`
© 2019 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia